Sibli Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.95 M
- Revenue Growth 1138.93%
- Profit Growth 741.49%
- Ebitda 403.48%
- Net Worth 50.70%
- Total Assets 129.65%
About Sibli Pharma
Sibli Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 August 2021 (Three years and six months 2 days old ). Its registered office is in Howrah, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹4.95 M.
Samir Shee and Swapna Shee serve as directors at the Company.
Company Details
-
Location
Howrah, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24100WB2021PTC247248
-
Company No.
247248
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Aug 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Sibli Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samir Shee
|
Director | 16-Aug-2021 | Current |
|
Swapna Shee
|
Director | 16-Aug-2021 | Current |
Financial Performance of Sibli Pharma.
Sibli Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1138.93% increase. The company also saw a substantial improvement in profitability, with a 741.49% increase in profit. The company's net worth Soared by an impressive increase of 50.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sibli Pharma?
Unlock access to Sibli Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹4.95 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.40 Cr
- Bank Of India : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Jul 2024 | Hdfc Bank Limited | ₹4.00 M | Open |
| 02 May 2022 | Bank Of India | ₹0.95 M | Open |
How Many Employees Work at Sibli Pharma?
Sibli Pharma has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sibli Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sibli Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.